Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.91 USD | +4.70% | -30.71% | -15.32% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.32% | 24Cr | |
+12.93% | 23TCr | |
+12.82% | 19TCr | |
+16.08% | 14TCr | |
+28.37% | 11TCr | |
+1.29% | 6.41TCr | |
+17.22% | 5.21TCr | |
+6.74% | 5.19TCr | |
+10.01% | 4.43TCr | |
+3.93% | 3.68TCr |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Earnings Flash (NPCE) NEUROPACE Reports Q3 Revenue $16.4M, vs. Street Est of $14.2M